Determination of HER-2/Neu Status in Hepatocellular Carcinoma Cases

Bacaksız, Ayşegül; Şahin, Feride İffet; Bilezikçi, Banu; Yılmaz, Zerrin

doi:10.1089/gte.2007.0095

Cited by 12 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have confirmed the high expression of ErvB-2 and ErbB-3 in cervical cancer tissues (Bacaksiz et al, 2008). This study found that the ErbB-3 binding protein Ebp1 is also highly expressed in cervical cancer tissues, suggesting that Ebp1 might be associated with the formation and development of cervical cancer.…”

Section: Discussionsupporting

confidence: 81%

Ebp1 protein expression in cervical cancer tissue and its significance

Liu

Yang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The objectives of this study were to observe the changes in expression of ErbB-3 binding protein (Ebp1) in cervical cancer and to investigate their clinic significance. We detected the expression level of Ebp1 in cancerous and adjacent tissues from 56 patients with cervical cancer. We identified 21 Ebp1 positive samples (37.5%) from among the 56 cervical cancer tissue samples and 5 Ebp1 positive samples (8.9%) in the corresponding adjacent tissues; the difference was statistically significant (P < 0.05). No statistically significant (P > 0.05) differences in the rates of positive Ebp1 expression were found between patients under 60 years of age and those equal to or over this age. No statistically significant differences (P > 0.05) were found between patients whose tumor diameters were under 5 cm and those with tumor diameters over 5 cm. No statistically significant differences (P > 0.05) in the Ebp1 positive rates were found among the cervical cancer samples when stratified by grade (I, II, or III). Together, these results demonstrate that Ebp1 protein expression is upregulated in cervical cancer tissues but is not related to clinical pathologic factors such as patient age or tumor 5497 Ebp1 protein expression in cervical cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 5496-5500 (2015) size or differentiation level, suggesting that Ebp1 plays an important role in the genesis and growth process of cervical cancer.

show abstract

Section: Discussionsupporting

confidence: 81%

Ebp1 protein expression in cervical cancer tissue and its significance

Liu

Yang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…HER-2 amplification has been reported in breast cancer, and a monoclonal antibody trastuzumab, has become an important therapeutic option for patients with HER-2 amplification (44). However, reports on the status of HER-2 in HCC are conflicting (45)(46)(47)(48). By FISH, we showed a high frequency of deletion for TP53.…”

Section: Detection Of Afp Mrnamentioning

confidence: 62%

“…Amplification of HER-2 was observed in 2 patients with higher CTC counts among the 11 patients analyzed. Such amplifications are uncommon in primary tumors of HCC (45,46), whereas some studies show frequent HER-2 overexpression in HCC (47,48). The frequency of HER-2 amplification of CTCs in HCC needs to be investigated with more patients so as to clarify whether it could be a candidate gene for targeted therapy in HCC.…”

Section: Detection Of Afp Mrnamentioning

confidence: 99%

Isolation of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation Strategy

Cao²,

Chen³

et al. 2011

Clinical Cancer Research

143

139

View full text Add to dashboard Cite

Purpose: To establish a sensitive and specific isolation and enumeration system for circulating tumor cells (CTC) in patients with hepatocellular carcinoma (HCC).Experimental Design: HCC cells were bound by biotinylated asialofetuin, a ligand of asialoglycoprotein receptor, and subsequently magnetically labeled by antibiotin antibody-coated magnetic beads, followed by magnetic separation. Isolated HCC cells were identified by immunofluorescence staining using Hep Par 1 antibody. The system was used to detect CTCs in 5 mL blood. Blood samples spiked with Hep3B cells (ranging from 10 to 810 cells) were used to determine recovery and sensitivity. Prevalence of CTCs was examined in samples from HCC patients, healthy volunteers, and patients with benign liver diseases or non-HCC cancers. CTC samples were also analyzed by FISH.Results: The average recovery was 61% or more at each spiking level. No healthy, benign liver disease or non-HCC cancer subjects had CTCs detected. CTCs were identified in 69 of 85 (81%) HCC patients, with an average of 19 AE 24 CTCs per 5 mL. Both the positivity rate and the number of CTCs were significantly correlated with tumor size, portal vein tumor thrombus, differentiation status, and the disease extent as classified by the TNM (tumor-node-metastasis) classification and the Milan criteria. HER-2 gene amplification and TP53 gene deletion were detected in CTCs.Conclusion: Our system provides a new tool allowing for highly sensitive and specific detection and genetic analysis of CTCs in HCC patients. It is likely clinically useful in diagnosis and monitoring of HCC and may have a role in clinical decision making.

show abstract

“…The EGFR is a member of a family of four closely related receptors: EGFR (ErbB-1), HER-2/neu (ErbB-2), HER-3 (ErbB-3) and HER-4 (ErbB-4). Interestingly, the expression of HER may play a role in the invasion, metastasis and progression of HCC (Bacaksiz et al, 2008;Zhang et al, 2010;Xu et al, 2011). Therefore, whether RHBDD1 participates in the above signaling pathways during HCC development remains wide open.…”

Section: Discussionmentioning

confidence: 99%